| Wissenschaftl. Titel | A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer |
| Erkrankung |
Lunge:
Lungenkrebs:
Nicht kleinzelliges Lungenkarzinom (NSCLC) - adjuvant
|
| weitere Prüfzentren | |
| Kurzprotokoll | Kurzprotokoll |
erstellt 12.07.2018 Sina Hehn
geändert 18.02.2022 Sina Hehn